Abstract This paper analyses the application of hybrid risk adjustment versus either prospective or concurrent risk adjustment formulae in the context of funding pharmaceutical benefits for the population of an integrated healthcare delivery organisation in Catalonia during years 2002 and 2003. We apply a mixed formula and find that, compared to prospective only models, a hybrid risk adjustment model increases incentives for efficiency in the provision for low risk individuals in health organisations, not only as a whole but also within each internal department, by reducing within-group variation of drug expenditures.
Introduction
Two major trends regarding pharmaceutical expenditure are currently taking place in developed countries. On the one hand, the introduction of generic drugs has contributed to a decrease in unit prices. On the other hand, expensive new and innovative molecules are being approved by drug regulatory agencies. The final impact of this trend is still unknown, although some initial effects are being observed. For example, the concentration of pharmaceutical expenditure among the most costly consumers is very high. While the top 10% of consumers in the United States represented 66% of pharmaceutical expenditure in 1996, this proportion decreased slightly to 64% in 2003; however, spending per person has more than doubled from US $1,823 to $3,925 [1] .
Such concentration in drug expenditure and in health expenditure in general has strong implications for the access to, and funding of, new drugs; raises equity concerns [1] ; and, within the context of private insurance, may promote incentives for risk selection [2] . More importantly in this paper, within the context of social insurance, such concentration of resources may make it difficult to identify efficient/inefficient areas of health organisations. However, beyond these facts there are relevant changes in population morbidity and mortality that require adjustment.
Studies aimed at understanding population patterns of drug consumption, costs and morbidity are less usual than required, and are hampered by the fact that individual data are divided between different sources in fragmented health care systems. However, recent research has revealed links between prescription drug expenditure and population demographics [3, 4] .
When citizens' health care is covered under universal coverage and public funding, there is a need for tools to allocate resources for drug expenditure at a population level that attempt to get value for money. In such situations, understanding morbidity becomes a key issue.
Several initiatives have been developed for setting prescription drug budgets in primary care, including the addition of incentives [5] and understanding of its variation [4, 6, 7] . However, prescription drug budgets affect all levels of care and not just primary care. The right approach should therefore allow for resource allocation at a population level, and should include all types of drug expenditure.
Under the term ''risk-adjustment'', there are several approaches aimed at explaining and predicting costs as well as utilisation by the population using health status data. These models are potentially useful in the context of compensating insurers and providers according to the risk they take, as reviewed in the applied drug literature in the United States [8] or Spain [9] . Risk adjustment has also been used to examine the economic profiling of physicians when claims data are grouped into episodes of care [10] . Most risk adjustment studies refer to the United States population. However, several papers report analysis of the application of prospective risk adjustment capitation payments in different countries (e.g. Australia [11] ; countries in Europe [12] such as Belgium [13] , the Netherlands [14] , Germany [15, 16] , and Switzerland [17] ; and Israel [18] ) using different information sets such as demographic information or diagnosis information. A wide review of the literature on evolution of risk adjustment can be found in Van de Ven and Ellis [19, 20] .
In designing a health care payment system, and within a private health insurance/provision system, any resource allocation has to solve the crucial trade-off between efficiency and selection [21, 22] depending on the information used in the configuration of the reimbursement scheme. Thus, if we include in the risk adjustment formula only ex ante individual information, which means that the reimbursement is fixed under a prospective risk adjustment scheme, we promote incentives for efficiency because health plans can benefit from the savings of reduced drug expenditure. However, under prospective payments, health plans may also benefit from selecting patients or benefits. In contrast, if we include only ex post individual information in the payment formula, we reduce the risk assumed by health plans, and therefore the incentive for risk selection, although also the incentive for efficiency. When such models use ex post information on cost instead of other indicators of need, they conform to what has been called in the literature a risk-sharing formula [23, 24, 25] , while if they use ex post information on diagnosis, they present a concurrent risk adjustment scheme [19] .
However, results in terms of incentives for efficiency and risk selection are sensitive to the type of information used in the payment system and depend on the specific environment. Thus, risk selection practices are expected to be less relevant when universal coverage is effective since all patients have access to health care, as is the case in our sample from a population under a National Health System. In such a case, resource allocation requires adjustment for morbidity since this is a key factor in expenditure.
The use of a mixed payment system for total health expenditure started to be explored in the literature in the past few decades [26, 27, 28] . However, there is a relatively new literature specifically addressing the predictability of drug expenditure [8, 29, 30] and the use of a mixed or hybrid risk adjustment formula with both prospective and concurrent information, with the aim of maximising incentives for efficiency while minimising incentives for risk selection [31, 32] . It is important to note that such risk adjustment strategies are useful even when risk selection is not an issue. There is an analogous problem to risk selection in the context of public provision. The key point is that health institutions receive a budget from health authorities, and risk adjustment allows identification of efficient and inefficient departments within the same health institution, and thus may avoid a scenario involving cross subsidies from efficient to inefficient departments. Conversely, if risk adjustment is not used, the budget of the health institution is considered as a whole and there are no incentives for efficiency within different departments of the organisation, promoting free-riding in inefficient departments. In a former article [9] , we have shown the extent of predictability of pharmaceutical expenditure according to morbidity grouped with the use of the Clinical Risk Groups (CRGs) classification system under different specification models applying risk adjustment (and compared our results to other articles in the literature). A recent comparison of the different information systems has been provided by the Society of Actuaries [33] .
In this article, we use individual data to analyse the relationship between drug expenditure and morbidity for a population belonging to an integrated healthcare organisation covered by the public health system in Catalonia, in the context of the Spanish National Health System. We present this analysis specifically for drug expenditure, given the increasing importance of drug expenditure in the total budget of health expenditures in countries such as Spain, where pharmaceuticals accounted for 22.9% of total health expenditure in 2005, compared to 19.2% in 1995 [34] . Budget allocation needs to take into account legitimate differences in cost according to morbidity. Integrated healthcare systems are increasingly searching for tools to allocate budgets and set the right incentives for health benefits. Thus, the use of a hybrid formula in the allocation of budgets allows the use of concurrent information for patients with specific conditions, which tends to concentrate drug expenditure benefits from its higher predictive power and compensates for deviations in drug expenditure that are explained by morbidity.
Methods

Data sources
We use individual data on prescription drug consumption and morbidity from an integrated healthcare organisation in Catalonia: Serveis de Salut Integrats del Baix Empordà (SSIBE). The organisation provides publicly funded health services (hospital care, primary care, and long-term care) to the population of the county of Baix Empordà. SSIBE is responsible for internally allocating the budget stemming from public funds received from the Catalonian public health authority in order to provide health service provision in the county. The providers taken into account are: Palamós Hospital, which has 100 beds for acute patients and 50 for skilled nursing care, and four primary care centres. The database includes all ambulatory pharmacy benefits for the population. Although citizens may also receive specialised benefits outside the organisation, data on these benefits and costs from outside the organisation were unavailable.
SSIBE has an information system that integrates clinical activities and costs. The main features that define this information system are: (1) unique identification patient files for all encounters (primary care, specialised care, and inpatient services), and (2) a decentralised activity file codified in ICD-9-CM by clinicians and reviewed by documentalists. The identification of each encounter allows the cost allocation, such as, in our case, pharmacy costs.
This research uses the following anonymised databases for the years 2002 and 2003: population database, encounters database, and pharmacy database. The first population database was created with information relative to all the resident population in Baix Empordà: 116,936 citizens. This paper is based on the analysis of only the four Health Basic Areas (ABS) managed by SSIBE, and refers to the morbidity and pharmaceutical expenditure of the 87,436 members who were covered during the years 2002 and 2003 by the integrated delivery system. Morbidity measurement is performed by the aggregation of the information on codified encounters of the population with the organisation (1,290,642 diagnosis and procedure codes). In this article, of the possible risk adjustment systems, we use the CRGs (version 1.2B), which allows individuals to be classified into mutually exclusive categories while preserving clinical significance, taking into account comorbidities and severity levels [35, 36] . Of the three different models provided by the CRG software, we use the concurrent model.
For each patient, a unique CRG as well as its corresponding aggregation into ACRG1, ACRG2 and ACRG3 is obtained. In this paper we describe the population through the highest level of aggregation (ACRG3), and for the estimations we use the second level of aggregation, ACRG2, to classify patients into morbidity groups. This level of aggregation originally had 176 mutually exclusive categories. However, we slightly modified these into 82 mutually exclusive categories, fully maintaining clinical significance by combining patients belonging to different CRGs of the same category but with different levels of severity, in order to avoid over-fitting in our estimation because of the very low numbers of patients in some groups.
Pharmaceutical expenditure information refers both to prescriptions provided by pharmacists publicly financed by Servei Català de Salut (CatSalut) as well as prescriptions to inpatients and medical ambulatory supply to ambulatory patients. Therefore, we include in the analysis ambulatory pharmaceutical prescriptions by doctors belonging to SSI-BE and billed by pharmacists, but also primary care, and specialised care prescriptions; the total pharmaceutical expenditure includes both public financing and private copayment (with a total of 1,206,008 primary care prescriptions, that added up to € 14,028,102 in 2002). This consumption information incorporates residents as well as other persons that received services from SSIBE. It also includes resident persons with access to international agreements and people with provisional authentication codes. This means that the total pharmaceutical consumption in the region cannot be fully allocated because part of this consumption does not correspond with the resident's file. Finally, there were 50,280 consumers of pharmaceuticals in 2002 (57.5% of the population), with a total individually allocated expenditure of € 13,026,913, from which there is a primary care prescription expenditure of € 12,091,603 and a hospital expenditure of € 935,310. Pharmaceutical consumption corresponding to prescriptions beyond SSIBE physicians or over-the-counter (OTC) drugs was not available. Table 1 lists the descriptive statistics of the sample. The population is almost equally distributed between males (50.53%) and females (49.47%), and the average pharmaceutical cost has increased from € 148. 
Study design
This paper estimates prospective, concurrent, and hybrid models using different information sets in order to predict drug expenditure in the subsequent year. Our objective is to examine the predictive power of each model, how well each explains future cost, and provides implications in terms of the application of a hybrid payment formula for the incentives of efficiency and risk selection in the pharmaceutical market. The basic model is provided by: DrugExp i;t ¼ f ðdemo i;tÀ1 ; HS i;tÀ1;t ; e i;t Þ Thus, the dependent variable, drug expenditure in year t for individual i, is explained by some independent variables or risk adjusters (individual demographic characteristics and health status information). Demographic information is provided by 12 age-gender cells. Prospective risk adjustment models predict actual drug expenditure with information on demographic characteristics and clinical status condition in year t-1. In contrast, concurrent risk adjustment models predict actual drug expenditure using demographic and actual information on clinical status. As a consequence, given the actual information, concurrent risk adjustment models explain a higher proportion of the variation in health expenditure than prospective risk adjustment models [19] . However, because of the asymmetry in the information used by health authorities and providers at each department of the institution, they do not solve the problem of identifying efficient and inefficient departments within that health institution. Thus, concurrent formulae using post-enrollment information, do not avoid the configuration of crosssubsidies between departments and therefore reduce incentives for efficiency. If a perfect capitation formula existed in order to set up prospective reimbursement [22] to each different department of the health institution, expected costs per individual would equal expected reimbursement, simultaneously solving the problems of incentives for efficiency in each department and in the health institution as a whole. Unfortunately, the consensus view in the literature is that a perfect capitation formula cannot be reached [19] .
Hybrid risk adjustment models combine both prospective and concurrent models. Pure prospective models promote incentives for efficiency but are unable to avoid free-riding among departments of the same institution. In contrast, the use of concurrent reimbursement models, such as those based on actual information on cost within the risk-sharing strategies, present lower incentives for freeriding within departments because payment or budget for each department is associated to its actual information, but incentives for efficiency are also reduced when using actual information on costs. The use of diagnosis-based risk adjustment models does not solve the problem of freeriding because they do not capture within-condition variation even with concurrent information [37] . Therefore, in an attempt to rescue the positive properties of both prospective and concurrent formulae, we propose the use of a hybrid risk adjustment model with information on health conditions that differs from the classification system used in the risk adjustment model. Hence, the population must be divided into two types. The health provider will receive a prospective reimbursement for the first type, while the reimbursement associated with the second type of patient under the hybrid system is set as a concurrent payment. The division of the population has to be such that the set of individuals to receive the prospective reimbursement are those for whom health care provision is not expected to suffer free-riding from other departments, with directly assigned expenditure. Conversely, in the population receiving the concurrent payment, we would like to have those patients whose provision is at risk of suffering freeriding from other departments within the health institution. In order to obtain results comparable with the related literature, we have utilised a set of 100 verifiable, expensive, predictive conditions (VEP100), as presented in Dudley et al. [31] . As an example, the first five VEP conditions used in the literature are anoxic brain damage, stomach cancer, acute myocardial infarction (AMI), leukaemia, and peritonitis; other types of cancer and HIV also belong to this list of conditions. The appropriateness of these conditions stems from the fact that, being verifiable (based on objective clinical measures) avoids the risk of simply classifying any expensive patient to this set of patients; being expensive and predictive, we select the type of patients whose provision might be at risk of suffering freeriding within departments in the same health institution because of, for example, long-term treatments.
Because the set of VEP100 conditions in our sample might be different from that of the United States in the literature, we checked its validity by comparing the relative cost weights of the set of patients with and without VEP100 conditions presented in Table 1 . As expected, patients suffering at least one of the specific VEP100 conditions systematically present drug expenditures much higher than the remainder of the patients (€ 603 vs € 92 in 2002, and € 724 vs € 106 in 2003). Because the problem of risk adjustment models is due to within-group variation in expected expenditures, we checked the distribution of the appearance of VEP100 conditions under the CRG classification system. In Table 2 , we observe how, in relative terms, 96% of healthy patients do not suffer any VEP100 conditions, while increasing the level of severity in the CRGs also increases the proportion of patients with at least one VEP100 condition, reaching around 97% of patients in the catastrophic conditions group. However, it is important to note that, in absolute terms, about 23% of all patients suffering at least one VEP100 condition (2, In this article, the specification used in estimations is linear regression since, although other specifications are considered in an earlier work [9] , they do not significantly increase the predictive power, and linear regression keeps interpretation for health policy makers simple. Other alternatives also being explored in the risk adjustment literature include the use of regression tree boosting to risk adjust health care cost predictions [10] . The methodology proposed in this paper, however, differs from other studies in three important specificities. First, we provide an initial approach for a sensitivity test in the use of hybrid risk adjustment, through the use of two different population divisions, suffering (1) at least one of the VEP100 conditions, and (2) more than one of the VEP100 conditions. The second difference with other approaches in the literature is the use of CRG instead of diagnostic cost group (DCG) as the patient classification system. Until now, studies on hybrid models had not used clinical categories in risk adjustment models. Finally, this is the first analysis of this type to examine hybrid risk adjustment strategies for a subset of the Spanish population, under a National Health System.
Results
Demographic information explains only 9% of the variation in drug expenditure (Model 1, R 2 = 0.09) (Table 3) . However, including health status information in the prospective model (model 2), the predictive power increases until R 2 = 0.21 (only CRG information; model 2a), 0.24 (demographic and CRG information; model 2b) or 0.27 (demographic, CRG information, and presence of at least one VEP100 condition; model 2c). Thus, the higher the quality of the information used in the prospective model, the better the predictive power, and including a dummy variable with the presence of a VEP100 condition improves the usual prospective model of the usual risk adjustment model using the CRG classification system. Concurrent models 3a-3c (using only CRG information, demographic and CRGs, or demographic, CRGs and presence of VEP100 conditions, respectively) behave in the same way, and increase the proportion of explained variance to its highest value of R 2 = 0.2893 (model 3c). When dividing the population into two parts depending on the presence of at least one VEP100 condition, the R 2 in the prospective models for patients without those conditions increases, and is similar to that of the concurrent model for the whole population, with an R 2 of 0.2769 (model 5c). The reason for this is that we have eliminated from that sample patients suffering VEP100 conditions (12.27% of the sample), who present a high variation of drug expenditure within CRG categories. At the same time, even in concurrent models, the R 2 of models for those patients with high variation in drug expenditure decreases to 0.2099 (model 4c). The hybrid models take into account the two sub-samples with concurrent information for patients with at least one VEP100 condition and prospective information for patients with no VEP100 condition. In order to calculate the R 2 for hybrid models, we first calculate the total error sum of squares for the combined populations (concurrent and prospective) as the error sum of squares for the concurrent population plus the error sum of squares from the prospective population. At the same time, the corrected total sum of squares is calculated as the sum of squares adjusted for the mean of the overall population. Finally, R 2 is defined as 1 minus the ratio of the error sum of squares to the corrected total sum of squares. This methodology has been used previously in the literature [31] . We obtain an R 2 for hybrid models of 0.2263 (model 6c), which is similar to the predictive power of the usual prospective model using demographic and health status information (model 2b), but in which efficiency incentives are higher for provision of pharmaceutical products for 87.73% of the population, and there are no incentives for risk selection for the provision of pharmaceutical products in those patients with VEP100 conditions who are thought to be at risk of suffering risk selection.
In a further attempt to check the validity of the hybrid risk adjustment model, we proceeded to develop a sensitivity analysis by changing the criteria for the division of the population. Thus, models 7-9 are similar to models 4-6, except that the prospective risk adjustment is assigned for patients suffering less than two VEP100 conditions (96.98%), and the concurrent risk adjustment is for patients with at least two VEP100 conditions (3.02%). In this model, the efficiency incentives remain for a higher proportion of the population, but the predictive power in the prospective model decreases to R 2 = 0.2199 (model 8c) because we have included patients with high variation in drug expenditure within CRG categories in the sub-sample. Therefore, incentives for risk selection for patients suffering one VEP100 condition still exist in this hybrid model. Conversely, the predictive power of the concurrent model for those patients with more than one VEP100 conditions increases hugely (R 2 = 0.3185 in model 7c), and the R 2 of hybrid models remain at the same level (cf. R 2 values of 0.2395 and 0.2263 in models 9c and 6c, respectively). The interpretation of this result is that the free variation in drug expenditure is especially concentrated in patients suffering one VEP100 condition because most of them still belong to relatively healthy CRG categories. It is important to note that our R 2 values are probably higher than would be expected in other national samples as all the providers are from a narrow geographical area, and hence drug expenditure and practice style variations are reduced compared to larger national samples. Table 4 presents the predictive ratios for the different risk adjustment models and by different groups of population. In the validating sample, the proportion of population with and without VEP100 conditions varies slightly (12.39% have at least one VEP100 condition and 3.05% have more than one). Results support those from the R 2 presented. All models (prospective, concurrent, and hybrid) benefit from including a dummy variable with the presence of VEP100 conditions. Hybrid models improve the predictive ratio for patients in most CRG categories, but especially when patients are ordered by deciles of drug expenditure or by the presence of VEP100 conditions. Also, the importance of prevalence of clinical conditions is evidenced by the fact that for patients in some CRG categories, prospective models present a better predictive ratio (closer to 1) than concurrent models, which can be explained by the timing of the diagnosis during the natural seasons of the year.
Conclusions
Development of mixed models of resource allocation that are simultaneously prospective and concurrent, is a goal for both publicly and privately funded health systems. Although risk adjustment models contribute to such a goal, specific mechanisms have to be defined. In this paper, we follow a hybrid risk adjustment approach in the literature that proposes dividing the population into two groups. We used the VEP100 set of verifiable, expensive, predictive conditions cited in the literature to split the population. We include the presence of such conditions as a risk adjuster in the prospective and concurrent models because they explain, to some extent, the high variation in drug expenditure within groups. Although it has not been shown here or elsewhere that this is the optimal way of dividing the population, in this paper we show how resource allocation can be improved in the delivery of pharmaceutical benefits for the population in a county in Catalonia served by an integrated healthcare organisation. Such a system could be applied to similar organisations, i.e. a ''yardstick competition'' model could be applied.
The prospective models shown here present a high predictive power. However, the hybrid models improve the predictive power for patients whose health provision is at risk of suffering free-riding through cross subsidies from efficient to inefficient departments within the health institution. Risk adjustment allows for better identification of efficiency in different departments, and hybrid risk adjustment limits the increase in the financial risk of efficient departments given unexpected changes in the morbidity of the population. The procedure is based on the concurrent elements of the reimbursement formula to fixed amounts according to the verifiable presence of some expensive conditions, and compensates deviations in drug expenditure, which are explained by morbidity given its high variation within groups. In such a situation there is a risk of up-coding, although this behaviour could be addressed through targeted auditing. In this research, we have taken the VEP conditions as given. However, we understand that there is a need to define specific VEP conditions for pharmaceutical expenditure since their impact on such expenditure might be different to that on total health expenditure. Future research is needed towards the application of hybrid risk adjustment models comparable to other studies in the literature, and with respect to the search for an optimal set of specific conditions in specific environments that solves the tradeoff between the efficiency of the entire health institution and of each department in that institution, avoiding free-riding at a minimal cost. Pharmaceutical expenditure is only one part of total expenditure. Therefore, we understand that an application focussing on total expenditure of a health benefits package is the next research approach required. 
